KRANESHARES TR QUADRATIC INT RTE VOL & INF HDG ETF IVOL 深 沪
等待开盘 04-06 09:30:00 美东时间
18.59
+0.010
+0.05%
华盛通- 最 高18.64
- 今 开18.58
- 成交量 39.08万股
- 最 低 18.5615
- 昨 收 18.58
- 总市值 4.76亿
- 52周最高 19.7934
- 市盈率 静 --
- 换手率 1.53%
- 52周最低 18.3008
- 委 比 -23.08%
- 总股本 2559.74万
- 历史最高 24.7834
- 量 比 2.01
- 振 幅 0.42%
- 历史最低 16.4677
- 每 手 1
- 风险率 0.27%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多美股ETF日报 | 有色金属回撤！三倍做空黄金ETF涨近18%，两倍做空白银ETF涨超15%
有色金属回撤！现货白银昨日收跌近9%，现货黄金昨日跌超4%；三倍做空黄金ETF涨近18%，两倍做空白银ETF涨超15%>>
2025-12-30 14:44
BRIEF-Shanghai Henlius Biotech Says Phase 1 Clinical Trial Of Nivolumab Biosimilar HLX18 Approved By FDA
Dec 19 (Reuters) - Shanghai Henlius Biotech Inc 2696.HK: PHASE 1 CLINICAL TRIAL OF NIVOLUMAB BIOSIMILAR HLX18 APPROVED BY UNITED STATES FDA Further company coverage: 2696.HK ((Reuters.Briefs@thomsonre...
2025-12-19 17:53
美股ETF日报 | AdvisorShares MSOS 2x Daily ETF涨107.85%，成交额8243.55万美元
AdvisorShares MSOS 2x Daily ETF涨107.85%；全美大麻ETF-AdvisorShares涨54.26%；ETFMG Alternative Harvest ETF涨42.77%
2025-12-13 08:15
BRIEF-Gilead: Discontinuation Of Phase 3 STAR-221 Study
Dec 12 (Reuters) - Gilead Sciences Inc GILD.O: GILEAD: DISCONTINUATION OF PHASE 3 STAR-221 STUDY GILEAD: DISCONTINUATION DECISION BASED ON RECOMMENDATION FROM INDEPENDENT DATA MONITORING COMMITTEE GIL...
2025-12-12 21:30
美股ETF日报 | Tradr 2X Long ASTS Daily ETF涨31.43%，成交额4578.26万美元
Tradr 2X Long ASTS Daily ETF涨31.43%；GraniteShares ETF Trust GraniteShares 2x Long SMCI Daily ETF涨18.47%；Defiance Daily Target 2X Long SMCI ETF is an ETF 涨18.37%
2025-10-02 17:25
美股ETF日报 | 黄金飙涨！三倍做多黄金矿业ETN涨超8%；二倍做多核电股SMR ETF大涨逾14%
金价连创新高！三倍做多黄金矿业ETN再涨超8%；二倍做多核电股SMR ETF大涨逾14%，美国最大小型模块化反应堆项目落地>>
2025-09-03 17:12
美股ETF日报 | 口服减肥药在糖尿病患者中显效果！2倍做多礼来ETF大涨11%；全美大麻ETF月内涨超90%
口服减肥药在糖尿病患者中显效果！2倍做多礼来ETF大涨11%；大麻股延续涨势！全美大麻ETF月内涨超90%>>
2025-08-27 17:34
BRIEF-Amgen Announces Positive Topline Phase 3 Results For Bemarituzumab In Fibroblast Growth Factor Receptor 2B (FGFR2b) Positive First-Line Gastric Cancer
June 30 (Reuters) - Amgen Inc AMGN.O: AMGEN ANNOUNCES POSITIVE TOPLINE PHASE 3 RESULTS FOR BEMARITUZUMAB IN FIBROBLAST GROWTH FACTOR RECEPTOR 2B (FGFR2B) POSITIVE FIRST-LINE GASTRIC CANCER AMGEN INC -...
2025-06-30 21:09
BRIEF-Replimune Presents New Analyses From The IGNYTE Study Of RP1 Plus Nivolumab In Anti-PD1 Failed Melanoma At The 2025 American Society Of Clinical Oncology (ASCO) Annual Meeting
June 1 (Reuters) - Replimune Group Inc REPL.O: REPLIMUNE PRESENTS NEW ANALYSES FROM THE IGNYTE STUDY OF RP1 PLUS NIVOLUMAB IN ANTI-PD1 FAILED MELANOMA AT THE 2025 AMERICAN SOCIETY OF CLINICAL ONCOLOGY...
2025-06-01 22:04
BRIEF-Bristol Myers Squibb Receives European Commission Approval For Perioperative Regimen Of Neoadjuvant Opdivo(Nivolumab) And Chemotherapy Followed By Adjuvant Opdivo For Resectable, High-Risk Non-Small Cell Lung Cancer With Pd-L1 Expression ≥1%
May 16 (Reuters) - Bristol-Myers Squibb Co BMY.N: BRISTOL MYERS SQUIBB RECEIVES EUROPEAN COMMISSION APPROVAL FOR PERIOPERATIVE REGIMEN OF NEOADJUVANT OPDIVO® (NIVOLUMAB) AND CHEMOTHERAPY FOLLOWED BY A...
2025-05-16 19:31
